Identification

Name
Salsalate
Accession Number
DB01399
Type
Small Molecule
Groups
Approved
Description

Salsalate is a nonsteroidal anti-inflammatory agent for oral administration. Salsalate's mode of action as an anti-inflammatory and antirheumatic agent may be due to inhibition of synthesis and release of prostaglandins. The usefulness of salicylic acid, the active in vivo product of salsalate, in the treatment of arthritic disorders has been established. In contrast to aspirin, salsalate causes no greater fecal gastrointestinal blood loss than placebo. Salsalate is readily soluble in the small intestine where it is partially hydrolyzed to two molecules of salicylic acid. A significant portion of the parent compound is absorbed unchanged and undergoes rapid esterase hydrolysis in the body. The parent compound has an elimination half-life of about 1 hour. Salicylic acid (the active metabolite) biotransformation is saturated at anti-inflammatory doses of salsalate. Such capacity limited biotransformation results in an increase in the half-life of salicylic acid from 3.5 to 16 or more hours.

Structure
Thumb
Synonyms
  • 2-Carboxyphenyl salicylate
  • Disalicylic acid
  • Disalicylsaeure
  • O-Salicylcylsalicylsaeure
  • O-Salicylsalicylic acid
  • Salicylic acid bimolecular ester
  • Salicyloxysalicylic acid
  • Salicyloylsalicylic acid
  • salicylsalicylic acid
  • Salsalato
  • Salsalatum
  • Sasapyrin
  • Sasapyrine
  • Sasapyrinum
External IDs
NSC-49171
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Disalcid - Tab 500mgTablet500 mgOral3 M Pharmaceuticals, A Division Of 3 M Canada Company1996-10-012002-07-09Canada
Disalcid - Tab 750mgTablet750 mgOral3 M Pharmaceuticals, A Division Of 3 M Canada Company1996-06-012002-07-09Canada
Disalcid Tab 500mgTablet500 mgOral3 M Pharmaceuticals, A Division Of 3 M Canada Company1993-12-311999-10-27Canada
Disalcid Tab 750mgTablet750 mgOral3 M Pharmaceuticals, A Division Of 3 M Canada Company1993-12-311999-10-27Canada
Unapproved/Other Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
DisalcidSalsalate (750 mg/1)TabletOralAvion Pharmaceuticals, Llc2014-09-182018-01-13Us
DisalcidSalsalate (500 mg/1)TabletOralAvion Pharmaceuticals, Llc2014-09-182018-01-13Us
SalsalateSalsalate (750 mg/1)TabletOralAmneal Pharmaceuticals2010-09-24Not applicableUs
SalsalateSalsalate (750 mg/1)TabletOralA S Medication Solutions2010-09-242017-06-20Us
SalsalateSalsalate (750 mg/1)Tablet, film coatedOralAphena Pharma Solutions Tennessee, Inc.2007-04-01Not applicableUs
SalsalateSalsalate (500 mg/1)TabletOralMajor1998-08-032017-08-29Us
SalsalateSalsalate (750 mg/1)TabletOralCarilion Materials Management2010-09-24Not applicableUs65162 0513 50 nlmimage10 210e90d4
SalsalateSalsalate (750 mg/1)Tablet, film coatedOralNationwide Laboratories2011-08-19Not applicableUs
SalsalateSalsalate (750 mg/1)TabletOralMethod Pharmaceuticals2016-11-23Not applicableUs
SalsalateSalsalate (500 mg/1)TabletOralAv Pak2015-02-182017-05-03Us
International/Other Brands
Disalcid
Categories
UNII
V9MO595C9I
CAS number
552-94-3
Weight
Average: 258.2262
Monoisotopic: 258.05282343
Chemical Formula
C14H10O5
InChI Key
WVYADZUPLLSGPU-UHFFFAOYSA-N
InChI
InChI=1S/C14H10O5/c15-11-7-3-1-5-9(11)14(18)19-12-8-4-2-6-10(12)13(16)17/h1-8,15H,(H,16,17)
IUPAC Name
2-(2-hydroxybenzoyloxy)benzoic acid
SMILES
OC(=O)C1=CC=CC=C1OC(=O)C1=CC=CC=C1O

Pharmacology

Indication

For relief of the signs and symptoms of rheumatoid arthritis, osteoarthritis and related rheumatic disorders.

Pharmacodynamics

Salsalate is a nonsteroidal anti-inflammatory agent for oral administration. Salsalate's mode of action as an anti-inflammatory and antirheumatic agent may be due to inhibition of synthesis and release of prostaglandins. The usefulness of salicylic acid, the active in vivo product of salsalate, in the treatment of arthritic disorders has been established. In contrast to aspirin, salsalate causes no greater fecal gastrointestinal blood loss than placebo.

Mechanism of action

The mode of anti-inflammatory action of salsalate and other nonsteroidal anti-inflammatory drugs is not fully defined, but appears to be primarily associated with inhibition of prostaglandin synthesis. This inhibition of prostaglandin synthesis is done through the inactivation of cyclooxygenase-1 (COX-1) and COX-2, which are reponsible for catalyzing the formation of prostaglandins in the arachidonic acid pathway. Although salicylic acid (the primary metabolite of salsalate) is a weak inhibitor of prostaglandin synthesis in vitro, salsalate appears to selectively inhibit prostaglandin synthesis in vivo, providing anti-inflammatory activity equivalent to aspirin and indomethacin. Unlike aspirin, salsalate does not inhibit platelet aggregation.

TargetActionsOrganism
AProstaglandin G/H synthase 2
inhibitor
Human
AProstaglandin G/H synthase 1
inhibitor
Human
Absorption

Salsalate is insoluble in acid gastric fluids (< 0.1 mg/ml at pH 1.0), but readily soluble in the small intestine where it is partially hydrolyzed to two molecules of salicylic acid. A significant portion of the parent compound is absorbed unchanged. The amount of salicylic acid available from salsalate is about 15% less than from aspirin, when the two drugs are administered on a salicylic acid molar equivalent basis (3.6 g salsalate/5 g aspirin). Food slows the absorption of all salicylates including salsalate.

Volume of distribution
Not Available
Protein binding

Salicylate: 90-95% bound at plasma salicylate concentrations <100 mcg/mL; 70-85% bound at concentrations of 100-400 mcg/mL; 25-60% bound at concentrations >400 mcg/mL.

Metabolism

Salsalate is readily soluble in the small intestine where it is partially hydrolyzed to two molecules of salicylic acid. A significant portion of the parent compound is absorbed unchanged and undergoes rapid esterase hydrolysis in the body.

Route of elimination
Not Available
Half life

The parent compound has an elimination half-life of about 1 hour. Salicylic acid (the active metabolite) biotransformation is saturated at anti-inflammatory doses of salsalate. Such capacity limited biotransformation results in an increase in the half-life of salicylic acid from 3.5 to 16 or more hours.

Clearance
Not Available
Toxicity

Death has followed ingestion of 10 to 30 g of salicylates in adults, but much larger amounts have been ingested without fatal outcome.

Affected organisms
  • Humans and other mammals
Pathways
PathwayCategory
Salsalate Action PathwayDrug action
Salsalate Action PathwayDrug action
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
(4R)-limoneneThe risk or severity of adverse effects can be increased when (4R)-limonene is combined with Salsalate.Investigational
16-BromoepiandrosteroneThe risk or severity of adverse effects can be increased when Salsalate is combined with 16-Bromoepiandrosterone.Investigational
19-norandrostenedioneThe risk or severity of adverse effects can be increased when Salsalate is combined with 19-norandrostenedione.Experimental, Illicit
5-androstenedioneThe risk or severity of adverse effects can be increased when Salsalate is combined with 5-androstenedione.Experimental, Illicit
AbciximabSalsalate may increase the anticoagulant activities of Abciximab.Approved
AcebutololSalsalate may decrease the antihypertensive activities of Acebutolol.Approved, Investigational
AceclofenacThe risk or severity of adverse effects can be increased when Salsalate is combined with Aceclofenac.Approved, Investigational
AcemetacinThe risk or severity of adverse effects can be increased when Salsalate is combined with Acemetacin.Approved, Experimental, Investigational
AcenocoumarolSalsalate may increase the anticoagulant activities of Acenocoumarol.Approved, Investigational
AdapaleneThe risk or severity of adverse effects can be increased when Adapalene is combined with Salsalate.Approved
AlaproclateAlaproclate may increase the antiplatelet activities of Salsalate.Experimental
AlclofenacThe risk or severity of adverse effects can be increased when Alclofenac is combined with Salsalate.Approved, Withdrawn
AlclometasoneThe risk or severity of adverse effects can be increased when Salsalate is combined with Alclometasone.Approved
AldosteroneThe risk or severity of adverse effects can be increased when Salsalate is combined with Aldosterone.Experimental, Investigational
Alendronic acidThe risk or severity of adverse effects can be increased when Salsalate is combined with Alendronic acid.Approved
AliskirenSalsalate may decrease the antihypertensive activities of Aliskiren.Approved, Investigational
AlminoprofenThe risk or severity of adverse effects can be increased when Alminoprofen is combined with Salsalate.Experimental
AlprenololSalsalate may decrease the antihypertensive activities of Alprenolol.Approved, Withdrawn
AlprostadilThe therapeutic efficacy of Alprostadil can be decreased when used in combination with Salsalate.Approved, Investigational
AmcinonideThe risk or severity of adverse effects can be increased when Salsalate is combined with Amcinonide.Approved
AmikacinThe risk or severity of nephrotoxicity can be increased when Salsalate is combined with Amikacin.Approved, Investigational, Vet Approved
AmilorideSalsalate may decrease the antihypertensive activities of Amiloride.Approved
Aminosalicylic AcidThe risk or severity of adverse effects can be increased when Salsalate is combined with Aminosalicylic Acid.Approved
AmlodipineThe therapeutic efficacy of Amlodipine can be decreased when used in combination with Salsalate.Approved
AncrodSalsalate may increase the anticoagulant activities of Ancrod.Approved, Investigational
AndrographolideThe risk or severity of adverse effects can be increased when Andrographolide is combined with Salsalate.Investigational
AndrostenedioneThe risk or severity of adverse effects can be increased when Salsalate is combined with Androstenedione.Experimental, Illicit
AnecortaveThe risk or severity of adverse effects can be increased when Salsalate is combined with Anecortave.Investigational
anecortave acetateThe risk or severity of adverse effects can be increased when Salsalate is combined with anecortave acetate.Investigational
AnisodamineThe risk or severity of adverse effects can be increased when Anisodamine is combined with Salsalate.Investigational
AntipyrineThe risk or severity of adverse effects can be increased when Salsalate is combined with Antipyrine.Approved, Investigational
Antithrombin III humanSalsalate may increase the anticoagulant activities of Antithrombin III human.Approved
AntrafenineThe risk or severity of adverse effects can be increased when Salsalate is combined with Antrafenine.Approved
ApixabanSalsalate may increase the anticoagulant activities of Apixaban.Approved
ApocyninThe risk or severity of adverse effects can be increased when Apocynin is combined with Salsalate.Investigational
ApramycinSalsalate may decrease the excretion rate of Apramycin which could result in a higher serum level.Experimental, Vet Approved
ApremilastThe risk or severity of adverse effects can be increased when Apremilast is combined with Salsalate.Approved, Investigational
ArbekacinSalsalate may decrease the excretion rate of Arbekacin which could result in a higher serum level.Approved, Investigational
ArdeparinSalsalate may increase the anticoagulant activities of Ardeparin.Approved, Investigational, Withdrawn
ArgatrobanSalsalate may increase the anticoagulant activities of Argatroban.Approved, Investigational
ArotinololSalsalate may decrease the antihypertensive activities of Arotinolol.Investigational
AsenapineSalsalate may decrease the antihypertensive activities of Asenapine.Approved
AtamestaneThe risk or severity of adverse effects can be increased when Salsalate is combined with Atamestane.Investigational
AtenololSalsalate may decrease the antihypertensive activities of Atenolol.Approved
AzapropazoneThe risk or severity of adverse effects can be increased when Azapropazone is combined with Salsalate.Withdrawn
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Salsalate.Approved
Azficel-TThe risk or severity of adverse effects can be increased when Salsalate is combined with Azficel-T.Approved, Investigational
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Salsalate.Approved, Investigational
AzosemideThe therapeutic efficacy of Azosemide can be decreased when used in combination with Salsalate.Investigational
BacitracinThe risk or severity of nephrotoxicity can be increased when Salsalate is combined with Bacitracin.Approved, Vet Approved
BalsalazideThe risk or severity of adverse effects can be increased when Balsalazide is combined with Salsalate.Approved, Investigational
BazedoxifeneSalsalate may increase the thrombogenic activities of Bazedoxifene.Approved, Investigational
BecaplerminSalsalate may increase the anticoagulant activities of Becaplermin.Approved, Investigational
Beclomethasone dipropionateThe risk or severity of gastrointestinal irritation can be increased when Beclomethasone dipropionate is combined with Salsalate.Approved, Investigational
BefunololSalsalate may decrease the antihypertensive activities of Befunolol.Experimental
BekanamycinSalsalate may decrease the excretion rate of Bekanamycin which could result in a higher serum level.Experimental
BenazeprilThe risk or severity of adverse effects can be increased when Salsalate is combined with Benazepril.Approved, Investigational
BendazacThe risk or severity of adverse effects can be increased when Bendazac is combined with Salsalate.Experimental
BendroflumethiazideThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Salsalate.Approved
BenorilateThe risk or severity of adverse effects can be increased when Benorilate is combined with Salsalate.Experimental
BenoxaprofenThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Salsalate.Withdrawn
BenzthiazideThe therapeutic efficacy of Benzthiazide can be decreased when used in combination with Salsalate.Approved
BenzydamineThe risk or severity of adverse effects can be increased when Benzydamine is combined with Salsalate.Approved
BepridilThe therapeutic efficacy of Bepridil can be decreased when used in combination with Salsalate.Approved, Withdrawn
BeraprostThe therapeutic efficacy of Beraprost can be decreased when used in combination with Salsalate.Investigational
BetamethasoneThe risk or severity of adverse effects can be increased when Salsalate is combined with Betamethasone.Approved, Vet Approved
BetaxololSalsalate may decrease the antihypertensive activities of Betaxolol.Approved, Investigational
BetrixabanThe risk or severity of bleeding can be increased when Betrixaban is combined with Salsalate.Approved, Investigational
BevantololSalsalate may decrease the antihypertensive activities of Bevantolol.Approved
BevoniumThe risk or severity of adverse effects can be increased when Bevonium is combined with Salsalate.Experimental
BimatoprostThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with Salsalate.Approved, Investigational
BisoprololSalsalate may decrease the antihypertensive activities of Bisoprolol.Approved
BivalirudinSalsalate may increase the anticoagulant activities of Bivalirudin.Approved, Investigational
BopindololSalsalate may decrease the antihypertensive activities of Bopindolol.Approved
BromfenacThe risk or severity of adverse effects can be increased when Bromfenac is combined with Salsalate.Approved
BucillamineThe risk or severity of adverse effects can be increased when Bucillamine is combined with Salsalate.Investigational
BucindololSalsalate may decrease the antihypertensive activities of Bucindolol.Investigational
BudesonideThe risk or severity of gastrointestinal irritation can be increased when Budesonide is combined with Salsalate.Approved
BufexamacThe risk or severity of adverse effects can be increased when Salsalate is combined with Bufexamac.Approved, Experimental
BufuralolSalsalate may decrease the antihypertensive activities of Bufuralol.Experimental, Investigational
BumadizoneThe risk or severity of adverse effects can be increased when Bumadizone is combined with Salsalate.Experimental
BumetanideThe therapeutic efficacy of Bumetanide can be decreased when used in combination with Salsalate.Approved
BupranololSalsalate may decrease the antihypertensive activities of Bupranolol.Approved
CandesartanThe risk or severity of adverse effects can be increased when Candesartan is combined with Salsalate.Experimental
Candesartan cilexetilThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Salsalate.Approved
CandoxatrilThe risk or severity of adverse effects can be increased when Salsalate is combined with Candoxatril.Experimental
CapsaicinThe risk or severity of adverse effects can be increased when Salsalate is combined with Capsaicin.Approved
CaptoprilThe risk or severity of adverse effects can be increased when Salsalate is combined with Captopril.Approved
Carbaspirin calciumThe risk or severity of adverse effects can be increased when Carbaspirin calcium is combined with Salsalate.Experimental, Investigational
Carboprost TromethamineThe therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Salsalate.Approved
CarprofenThe risk or severity of adverse effects can be increased when Carprofen is combined with Salsalate.Approved, Vet Approved, Withdrawn
CarteololSalsalate may decrease the antihypertensive activities of Carteolol.Approved
CarvedilolSalsalate may decrease the antihypertensive activities of Carvedilol.Approved, Investigational
CastanospermineThe risk or severity of adverse effects can be increased when Castanospermine is combined with Salsalate.Experimental
CelecoxibThe risk or severity of adverse effects can be increased when Celecoxib is combined with Salsalate.Approved, Investigational
CeliprololSalsalate may decrease the antihypertensive activities of Celiprolol.Approved, Investigational
CertoparinSalsalate may increase the anticoagulant activities of Certoparin.Approved, Investigational
ChloroquineThe risk or severity of adverse effects can be increased when Chloroquine is combined with Salsalate.Approved, Investigational, Vet Approved
ChlorothiazideThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Salsalate.Approved, Vet Approved
ChlorotrianiseneSalsalate may increase the thrombogenic activities of Chlorotrianisene.Investigational, Withdrawn
ChlorphenesinThe risk or severity of adverse effects can be increased when Salsalate is combined with Chlorphenesin.Approved, Vet Approved, Withdrawn
ChlorthalidoneThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Salsalate.Approved
CholestyramineCholestyramine can cause a decrease in the absorption of Salsalate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Choline magnesium trisalicylateThe risk or severity of adverse effects can be increased when Salsalate is combined with Choline magnesium trisalicylate.Approved
CiclesonideThe risk or severity of adverse effects can be increased when Salsalate is combined with Ciclesonide.Approved, Investigational
CilazaprilThe risk or severity of adverse effects can be increased when Salsalate is combined with Cilazapril.Approved
CimicoxibThe risk or severity of adverse effects can be increased when Salsalate is combined with Cimicoxib.Investigational
CinoxacinSalsalate may increase the neuroexcitatory activities of Cinoxacin.Approved, Investigational, Withdrawn
CiprofloxacinSalsalate may increase the neuroexcitatory activities of Ciprofloxacin.Approved, Investigational
CisplatinThe risk or severity of adverse effects can be increased when Salsalate is combined with Cisplatin.Approved
CitalopramCitalopram may increase the antiplatelet activities of Salsalate.Approved
ClobetasolThe risk or severity of adverse effects can be increased when Salsalate is combined with Clobetasol.Approved, Investigational
Clobetasol propionateThe risk or severity of adverse effects can be increased when Salsalate is combined with Clobetasol propionate.Approved
ClobetasoneThe risk or severity of adverse effects can be increased when Salsalate is combined with Clobetasone.Approved
ClocortoloneThe risk or severity of adverse effects can be increased when Salsalate is combined with Clocortolone.Approved
Clodronic AcidThe risk or severity of adverse effects can be increased when Salsalate is combined with Clodronic Acid.Approved, Investigational, Vet Approved
ClonixinThe risk or severity of adverse effects can be increased when Clonixin is combined with Salsalate.Approved
CloprostenolThe therapeutic efficacy of Cloprostenol can be decreased when used in combination with Salsalate.Vet Approved
CloranololSalsalate may decrease the antihypertensive activities of Cloranolol.Experimental
ClorindioneSalsalate may increase the anticoagulant activities of Clorindione.Experimental
ColesevelamColesevelam can cause a decrease in the absorption of Salsalate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ColestipolColestipol can cause a decrease in the absorption of Salsalate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Conjugated estrogensSalsalate may increase the thrombogenic activities of Conjugated estrogens.Approved
Cortexolone 17α-propionateThe risk or severity of adverse effects can be increased when Salsalate is combined with Cortexolone 17α-propionate.Investigational
CorticosteroneThe risk or severity of adverse effects can be increased when Salsalate is combined with Corticosterone.Experimental
Cortisone acetateThe risk or severity of adverse effects can be increased when Salsalate is combined with Cortisone acetate.Approved, Investigational
CurcuminThe risk or severity of adverse effects can be increased when Curcumin is combined with Salsalate.Approved, Investigational
CyclopenthiazideThe therapeutic efficacy of Cyclopenthiazide can be decreased when used in combination with Salsalate.Experimental
CyclosporineThe risk or severity of renal failure and hypertension can be increased when Salsalate is combined with Cyclosporine.Approved, Investigational, Vet Approved
Dabigatran etexilateSalsalate may increase the anticoagulant activities of Dabigatran etexilate.Approved
DaidzeinSalsalate may increase the thrombogenic activities of Daidzein.Experimental
DalteparinSalsalate may increase the anticoagulant activities of Dalteparin.Approved
DanaparoidSalsalate may increase the anticoagulant activities of Danaparoid.Approved, Withdrawn
DapoxetineDapoxetine may increase the antiplatelet activities of Salsalate.Investigational
DarexabanSalsalate may increase the anticoagulant activities of Darexaban.Investigational
DeferasiroxThe risk or severity of adverse effects can be increased when Salsalate is combined with Deferasirox.Approved, Investigational
DeflazacortThe risk or severity of adverse effects can be increased when Salsalate is combined with Deflazacort.Approved, Investigational
DelaprilThe risk or severity of adverse effects can be increased when Salsalate is combined with Delapril.Investigational
DesipramineSalsalate may decrease the antihypertensive activities of Desipramine.Approved, Investigational
DesirudinSalsalate may increase the anticoagulant activities of Desirudin.Approved
DesmopressinThe risk or severity of adverse effects can be increased when Salsalate is combined with Desmopressin.Approved
DesonideThe risk or severity of adverse effects can be increased when Salsalate is combined with Desonide.Approved, Investigational
DesoximetasoneThe risk or severity of adverse effects can be increased when Salsalate is combined with Desoximetasone.Approved
Desoxycorticosterone acetateThe risk or severity of adverse effects can be increased when Salsalate is combined with Desoxycorticosterone acetate.Approved
Desoxycorticosterone PivalateThe risk or severity of adverse effects can be increased when Salsalate is combined with Desoxycorticosterone Pivalate.Experimental, Vet Approved
DesvenlafaxineDesvenlafaxine may increase the antiplatelet activities of Salsalate.Approved, Investigational
DexamethasoneThe risk or severity of gastrointestinal irritation can be increased when Dexamethasone is combined with Salsalate.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateThe risk or severity of adverse effects can be increased when Salsalate is combined with Dexamethasone isonicotinate.Vet Approved
DexibuprofenThe risk or severity of adverse effects can be increased when Salsalate is combined with Dexibuprofen.Approved, Investigational
DexketoprofenThe risk or severity of adverse effects can be increased when Dexketoprofen is combined with Salsalate.Approved, Investigational
DexniguldipineThe therapeutic efficacy of Dexniguldipine can be decreased when used in combination with Salsalate.Experimental
DextranSalsalate may increase the anticoagulant activities of Dextran.Approved, Investigational, Vet Approved
DibekacinSalsalate may decrease the excretion rate of Dibekacin which could result in a higher serum level.Experimental
Dibotermin alfaThe risk or severity of adverse effects can be increased when Salsalate is combined with Dibotermin alfa.Approved, Investigational
DiclofenacThe risk or severity of adverse effects can be increased when Diclofenac is combined with Salsalate.Approved, Vet Approved
DicoumarolSalsalate may increase the anticoagulant activities of Dicoumarol.Approved
DienestrolSalsalate may increase the thrombogenic activities of Dienestrol.Approved, Investigational
DiethylstilbestrolSalsalate may increase the thrombogenic activities of Diethylstilbestrol.Approved, Investigational
DifenpiramideThe risk or severity of adverse effects can be increased when Difenpiramide is combined with Salsalate.Experimental
DiflorasoneThe risk or severity of adverse effects can be increased when Salsalate is combined with Diflorasone.Approved
DiflunisalThe risk or severity of adverse effects can be increased when Diflunisal is combined with Salsalate.Approved, Investigational
DifluocortoloneThe risk or severity of adverse effects can be increased when Salsalate is combined with Difluocortolone.Approved, Investigational, Withdrawn
DifluprednateThe risk or severity of adverse effects can be increased when Salsalate is combined with Difluprednate.Approved
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Salsalate.Approved
DihydrostreptomycinSalsalate may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Investigational, Vet Approved
DiltiazemThe therapeutic efficacy of Diltiazem can be decreased when used in combination with Salsalate.Approved, Investigational
DinoprostThe therapeutic efficacy of Dinoprost can be decreased when used in combination with Salsalate.Investigational
Dinoprost TromethamineThe therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with Salsalate.Approved, Vet Approved
DinoprostoneThe therapeutic efficacy of Dinoprostone can be decreased when used in combination with Salsalate.Approved
DiphenadioneSalsalate may increase the anticoagulant activities of Diphenadione.Experimental
DoxazosinThe therapeutic efficacy of Doxazosin can be decreased when used in combination with Salsalate.Approved
DrospirenoneSalsalate may increase the hyperkalemic activities of Drospirenone.Approved
DroxicamThe risk or severity of adverse effects can be increased when Salsalate is combined with Droxicam.Withdrawn
DuloxetineDuloxetine may increase the antiplatelet activities of Salsalate.Approved
DuvelisibThe risk or severity of adverse effects can be increased when Duvelisib is combined with Salsalate.Investigational
E-6201The risk or severity of adverse effects can be increased when E-6201 is combined with Salsalate.Investigational
Edetic AcidSalsalate may increase the anticoagulant activities of Edetic Acid.Approved, Vet Approved
EdoxabanSalsalate may increase the anticoagulant activities of Edoxaban.Approved
EfonidipineThe therapeutic efficacy of Efonidipine can be decreased when used in combination with Salsalate.Approved, Investigational
EnalaprilThe risk or severity of adverse effects can be increased when Salsalate is combined with Enalapril.Approved, Vet Approved
EnalaprilatThe risk or severity of adverse effects can be increased when Salsalate is combined with Enalaprilat.Approved
EnoxacinSalsalate may increase the neuroexcitatory activities of Enoxacin.Approved, Investigational
EnoxaparinSalsalate may increase the anticoagulant activities of Enoxaparin.Approved
EnprostilThe therapeutic efficacy of Enprostil can be decreased when used in combination with Salsalate.Experimental
EpanololSalsalate may decrease the antihypertensive activities of Epanolol.Experimental
EpimestrolSalsalate may increase the thrombogenic activities of Epimestrol.Experimental
EpirizoleThe risk or severity of adverse effects can be increased when Epirizole is combined with Salsalate.Approved
EpitizideThe therapeutic efficacy of Epitizide can be decreased when used in combination with Salsalate.Experimental
EplerenoneSalsalate may decrease the antihypertensive activities of Eplerenone.Approved
EpoprostenolThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Salsalate.Approved
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Salsalate.Approved
EquileninThe risk or severity of adverse effects can be increased when Salsalate is combined with Equilenin.Experimental
EquilinThe risk or severity of adverse effects can be increased when Salsalate is combined with Equilin.Approved
EquolSalsalate may increase the thrombogenic activities of Equol.Investigational
EsatenololSalsalate may decrease the antihypertensive activities of Esatenolol.Experimental
EscitalopramEscitalopram may increase the antiplatelet activities of Salsalate.Approved, Investigational
EsmololSalsalate may decrease the antihypertensive activities of Esmolol.Approved
Estradiol acetateSalsalate may increase the thrombogenic activities of Estradiol acetate.Approved, Investigational, Vet Approved
Estradiol cypionateSalsalate may increase the thrombogenic activities of Estradiol cypionate.Approved, Investigational, Vet Approved
Estradiol valerateSalsalate may increase the thrombogenic activities of Estradiol valerate.Approved, Investigational, Vet Approved
EstriolSalsalate may increase the thrombogenic activities of Estriol.Approved, Investigational, Vet Approved
Estrogens, esterifiedSalsalate may increase the thrombogenic activities of Estrogens, esterified.Approved
EstroneThe risk or severity of adverse effects can be increased when Salsalate is combined with Estrone.Approved
Estrone sulfateThe risk or severity of adverse effects can be increased when Salsalate is combined with Estrone sulfate.Approved
Etacrynic acidThe therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Salsalate.Approved, Investigational
EtanerceptThe risk or severity of adverse effects can be increased when Etanercept is combined with Salsalate.Approved, Investigational
EthenzamideThe risk or severity of adverse effects can be increased when Ethenzamide is combined with Salsalate.Experimental
Ethyl biscoumacetateSalsalate may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
Etidronic acidThe risk or severity of adverse effects can be increased when Salsalate is combined with Etidronic acid.Approved
EtodolacThe risk or severity of adverse effects can be increased when Etodolac is combined with Salsalate.Approved, Investigational, Vet Approved
EtofenamateThe risk or severity of adverse effects can be increased when Etofenamate is combined with Salsalate.Approved, Investigational
EtoperidoneEtoperidone may increase the antiplatelet activities of Salsalate.Withdrawn
EtoricoxibThe risk or severity of adverse effects can be increased when Salsalate is combined with Etoricoxib.Approved, Investigational
Evening primrose oilThe risk or severity of adverse effects can be increased when Evening primrose oil is combined with Salsalate.Investigational, Nutraceutical
ExisulindThe risk or severity of adverse effects can be increased when Exisulind is combined with Salsalate.Investigational
FelbinacThe risk or severity of adverse effects can be increased when Felbinac is combined with Salsalate.Experimental
FelodipineThe therapeutic efficacy of Felodipine can be decreased when used in combination with Salsalate.Approved, Investigational
FenbufenThe risk or severity of adverse effects can be increased when Fenbufen is combined with Salsalate.Approved
FenoprofenThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Salsalate.Approved
FenprostaleneThe therapeutic efficacy of Fenprostalene can be decreased when used in combination with Salsalate.Vet Approved
FentiazacThe risk or severity of adverse effects can be increased when Fentiazac is combined with Salsalate.Experimental
FeprazoneThe risk or severity of adverse effects can be increased when Feprazone is combined with Salsalate.Experimental
Ferulic acidThe risk or severity of adverse effects can be increased when Ferulic acid is combined with Salsalate.Experimental
FimasartanThe risk or severity of adverse effects can be increased when Fimasartan is combined with Salsalate.Approved, Investigational
FleroxacinSalsalate may increase the neuroexcitatory activities of Fleroxacin.Approved
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Salsalate.Approved, Withdrawn
FluasteroneThe risk or severity of adverse effects can be increased when Salsalate is combined with Fluasterone.Investigational
FludrocortisoneThe risk or severity of adverse effects can be increased when Salsalate is combined with Fludrocortisone.Approved, Investigational
FluindioneSalsalate may increase the anticoagulant activities of Fluindione.Approved, Investigational
FlumequineSalsalate may increase the neuroexcitatory activities of Flumequine.Withdrawn
FlumethasoneThe risk or severity of adverse effects can be increased when Salsalate is combined with Flumethasone.Approved, Vet Approved
FlunisolideThe risk or severity of adverse effects can be increased when Salsalate is combined with Flunisolide.Approved, Investigational
FlunixinThe risk or severity of adverse effects can be increased when Flunixin is combined with Salsalate.Vet Approved
FlunoxaprofenThe risk or severity of adverse effects can be increased when Flunoxaprofen is combined with Salsalate.Experimental
Fluocinolone AcetonideThe risk or severity of adverse effects can be increased when Salsalate is combined with Fluocinolone Acetonide.Approved, Investigational, Vet Approved
FluocinonideThe risk or severity of adverse effects can be increased when Salsalate is combined with Fluocinonide.Approved, Investigational
FluocortoloneThe risk or severity of adverse effects can be increased when Salsalate is combined with Fluocortolone.Approved, Withdrawn
FluorometholoneThe risk or severity of adverse effects can be increased when Salsalate is combined with Fluorometholone.Approved, Investigational
FluoxetineFluoxetine may increase the antiplatelet activities of Salsalate.Approved, Vet Approved
FluprednideneThe risk or severity of adverse effects can be increased when Salsalate is combined with Fluprednidene.Approved, Withdrawn
FluprednisoloneThe risk or severity of adverse effects can be increased when Salsalate is combined with Fluprednisolone.Approved
FluprostenolThe therapeutic efficacy of Fluprostenol can be decreased when used in combination with Salsalate.Vet Approved
FlurandrenolideThe risk or severity of adverse effects can be increased when Salsalate is combined with Flurandrenolide.Approved
FlurbiprofenThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Salsalate.Approved, Investigational
FluticasoneThe risk or severity of adverse effects can be increased when Salsalate is combined with Fluticasone.Approved, Experimental, Investigational
Fluticasone furoateThe risk or severity of adverse effects can be increased when Salsalate is combined with Fluticasone furoate.Approved
Fluticasone propionateThe risk or severity of gastrointestinal irritation can be increased when Fluticasone propionate is combined with Salsalate.Approved
FluvoxamineFluvoxamine may increase the antiplatelet activities of Salsalate.Approved, Investigational
Folic AcidThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Salsalate.Approved, Nutraceutical, Vet Approved
FondaparinuxSalsalate may increase the anticoagulant activities of Fondaparinux sodium.Approved, Investigational
ForasartanThe risk or severity of adverse effects can be increased when Forasartan is combined with Salsalate.Experimental
FormestaneThe risk or severity of adverse effects can be increased when Salsalate is combined with Formestane.Approved, Investigational, Withdrawn
FosinoprilThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Salsalate is combined with Fosinopril.Approved
FramycetinSalsalate may decrease the excretion rate of Framycetin which could result in a higher serum level.Approved
FurosemideThe therapeutic efficacy of Furosemide can be decreased when used in combination with Salsalate.Approved, Vet Approved
GabexateSalsalate may increase the anticoagulant activities of Gabexate.Investigational
GarenoxacinSalsalate may increase the neuroexcitatory activities of Garenoxacin.Investigational
GatifloxacinSalsalate may increase the neuroexcitatory activities of Gatifloxacin.Approved, Investigational
GemeprostThe therapeutic efficacy of Gemeprost can be decreased when used in combination with Salsalate.Approved, Withdrawn
GemifloxacinSalsalate may increase the neuroexcitatory activities of Gemifloxacin.Approved, Investigational
GeneticinSalsalate may decrease the excretion rate of Geneticin which could result in a higher serum level.Experimental
GenisteinSalsalate may increase the thrombogenic activities of Genistein.Investigational
GentamicinSalsalate may decrease the excretion rate of Gentamicin which could result in a higher serum level.Approved, Vet Approved
GENTAMICIN C1ASalsalate may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level.Experimental
GinsengThe risk or severity of adverse effects can be increased when Salsalate is combined with Ginseng.Approved, Investigational, Nutraceutical
GlipizideThe protein binding of Glipizide can be decreased when combined with Salsalate.Approved, Investigational
GlyburideThe protein binding of Glyburide can be decreased when combined with Salsalate.Approved
GrepafloxacinSalsalate may increase the neuroexcitatory activities of Grepafloxacin.Approved, Investigational, Withdrawn
GuacetisalThe risk or severity of adverse effects can be increased when Guacetisal is combined with Salsalate.Experimental
GuanfacineThe therapeutic efficacy of Guanfacine can be decreased when used in combination with Salsalate.Approved, Investigational
HalcinonideThe risk or severity of adverse effects can be increased when Salsalate is combined with Halcinonide.Approved, Investigational, Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when Salsalate is combined with Haloperidol.Approved
HE3286The risk or severity of adverse effects can be increased when Salsalate is combined with HE3286.Investigational
HeparinSalsalate may increase the anticoagulant activities of Heparin.Approved, Investigational
HexestrolSalsalate may increase the thrombogenic activities of Hexestrol.Withdrawn
HigenamineThe risk or severity of adverse effects can be increased when Higenamine is combined with Salsalate.Investigational
HydralazineSalsalate may decrease the antihypertensive activities of Hydralazine.Approved
HydrochlorothiazideThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Salsalate.Approved, Vet Approved
HydrocortisoneThe risk or severity of gastrointestinal irritation can be increased when Hydrocortisone is combined with Salsalate.Approved, Vet Approved
Hydrocortisone acetateThe risk or severity of gastrointestinal irritation can be increased when Hydrocortisone acetate is combined with Salsalate.Approved, Vet Approved
Hydrocortisone butyrateThe risk or severity of gastrointestinal irritation can be increased when Hydrocortisone butyrate is combined with Salsalate.Approved, Vet Approved
HydroflumethiazideThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Salsalate.Approved, Investigational
Hygromycin BSalsalate may decrease the excretion rate of Hygromycin B which could result in a higher serum level.Vet Approved
IbandronateThe risk or severity of gastrointestinal bleeding can be increased when Salsalate is combined with Ibandronate.Approved, Investigational
IbuprofenThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Salsalate.Approved
IbuproxamThe risk or severity of adverse effects can be increased when Ibuproxam is combined with Salsalate.Withdrawn
IcatibantThe risk or severity of adverse effects can be increased when Icatibant is combined with Salsalate.Approved, Investigational
IcosapentThe risk or severity of adverse effects can be increased when Salsalate is combined with Icosapent.Approved, Nutraceutical
IdraparinuxSalsalate may increase the anticoagulant activities of Idraparinux.Investigational
IloprostThe therapeutic efficacy of Iloprost can be decreased when used in combination with Salsalate.Approved, Investigational
ImidaprilThe risk or severity of adverse effects can be increased when Salsalate is combined with Imidapril.Investigational
Imidazole salicylateThe risk or severity of adverse effects can be increased when Imidazole salicylate is combined with Salsalate.Experimental
IndalpineIndalpine may increase the antiplatelet activities of Salsalate.Investigational, Withdrawn
IndapamideThe therapeutic efficacy of Indapamide can be decreased when used in combination with Salsalate.Approved
IndenololSalsalate may decrease the antihypertensive activities of Indenolol.Withdrawn
IndobufenThe risk or severity of adverse effects can be increased when Indobufen is combined with Salsalate.Investigational
IndomethacinThe risk or severity of adverse effects can be increased when Indomethacin is combined with Salsalate.Approved, Investigational
IndoprofenThe risk or severity of adverse effects can be increased when Indoprofen is combined with Salsalate.Withdrawn
IrbesartanThe risk or severity of adverse effects can be increased when Irbesartan is combined with Salsalate.Approved, Investigational
IsepamicinSalsalate may decrease the excretion rate of Isepamicin which could result in a higher serum level.Experimental
IsoxicamThe risk or severity of adverse effects can be increased when Isoxicam is combined with Salsalate.Withdrawn
IsradipineThe therapeutic efficacy of Isradipine can be decreased when used in combination with Salsalate.Approved, Investigational
IstaroximeThe risk or severity of adverse effects can be increased when Salsalate is combined with Istaroxime.Investigational
KanamycinSalsalate may decrease the excretion rate of Kanamycin which could result in a higher serum level.Approved, Investigational, Vet Approved
KebuzoneThe risk or severity of adverse effects can be increased when Kebuzone is combined with Salsalate.Experimental
KetoprofenThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Salsalate.Approved, Vet Approved
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with Salsalate.Approved
LabetalolSalsalate may decrease the antihypertensive activities of Labetalol.Approved
LacidipineThe therapeutic efficacy of Lacidipine can be decreased when used in combination with Salsalate.Approved, Investigational
LandiololSalsalate may decrease the antihypertensive activities of Landiolol.Investigational
LatanoprostThe therapeutic efficacy of Latanoprost can be decreased when used in combination with Salsalate.Approved, Investigational
Latanoprostene BunodThe therapeutic efficacy of Latanoprostene Bunod can be decreased when used in combination with Salsalate.Approved, Investigational
LeflunomideThe risk or severity of adverse effects can be increased when Leflunomide is combined with Salsalate.Approved, Investigational
LepirudinSalsalate may increase the anticoagulant activities of Lepirudin.Approved
LercanidipineThe therapeutic efficacy of Lercanidipine can be decreased when used in combination with Salsalate.Approved, Investigational
LetaxabanSalsalate may increase the anticoagulant activities of Letaxaban.Investigational
LevobetaxololSalsalate may decrease the antihypertensive activities of Levobetaxolol.Approved, Investigational
LevobunololSalsalate may decrease the antihypertensive activities of Levobunolol.Approved
LevofloxacinSalsalate may increase the neuroexcitatory activities of Levofloxacin.Approved, Investigational
LevomilnacipranLevomilnacipran may increase the antiplatelet activities of Salsalate.Approved, Investigational
LimaprostThe therapeutic efficacy of Limaprost can be decreased when used in combination with Salsalate.Approved, Investigational
LisinoprilThe risk or severity of adverse effects can be increased when Salsalate is combined with Lisinopril.Approved, Investigational
LisofyllineThe risk or severity of adverse effects can be increased when Lisofylline is combined with Salsalate.Investigational
Lithium cationThe serum concentration of Lithium can be increased when it is combined with Salsalate.Experimental
LomefloxacinSalsalate may increase the neuroexcitatory activities of Lomefloxacin.Approved, Investigational
LonazolacThe risk or severity of adverse effects can be increased when Lonazolac is combined with Salsalate.Experimental
LornoxicamThe risk or severity of adverse effects can be increased when Salsalate is combined with Lornoxicam.Approved, Investigational
LosartanThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Losartan is combined with Salsalate.Approved
LoteprednolThe risk or severity of adverse effects can be increased when Salsalate is combined with Loteprednol.Approved
LoxoprofenThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Salsalate.Approved, Investigational
LubiprostoneThe therapeutic efficacy of Lubiprostone can be decreased when used in combination with Salsalate.Approved, Investigational
LumiracoxibThe risk or severity of adverse effects can be increased when Lumiracoxib is combined with Salsalate.Approved, Investigational
LuprostiolThe therapeutic efficacy of Luprostiol can be decreased when used in combination with Salsalate.Vet Approved
Magnesium salicylateThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Salsalate.Approved
ManidipineThe therapeutic efficacy of Manidipine can be decreased when used in combination with Salsalate.Approved, Investigational
MasoprocolThe risk or severity of adverse effects can be increased when Masoprocol is combined with Salsalate.Approved, Investigational
ME-609The risk or severity of adverse effects can be increased when Salsalate is combined with ME-609.Investigational
Meclofenamic acidThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Salsalate.Approved, Vet Approved
MedrysoneThe risk or severity of adverse effects can be increased when Salsalate is combined with Medrysone.Approved
Mefenamic acidThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Salsalate.Approved
MelagatranSalsalate may increase the anticoagulant activities of Melagatran.Experimental
MelengestrolThe risk or severity of adverse effects can be increased when Salsalate is combined with Melengestrol.Vet Approved
MeloxicamThe risk or severity of adverse effects can be increased when Meloxicam is combined with Salsalate.Approved, Vet Approved
MepindololSalsalate may decrease the antihypertensive activities of Mepindolol.Experimental
MesalazineThe risk or severity of adverse effects can be increased when Mesalazine is combined with Salsalate.Approved
MestranolSalsalate may increase the thrombogenic activities of Mestranol.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Metamizole is combined with Salsalate.Approved, Investigational, Withdrawn
MethallenestrilSalsalate may increase the thrombogenic activities of Methallenestril.Experimental
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Salsalate.Approved
MethyclothiazideThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Salsalate.Approved
Methyl salicylateThe therapeutic efficacy of Methyl salicylate can be decreased when used in combination with Salsalate.Approved, Vet Approved
MethylprednisoloneThe risk or severity of gastrointestinal irritation can be increased when Methylprednisolone is combined with Salsalate.Approved, Vet Approved
MetipranololSalsalate may decrease the antihypertensive activities of Metipranolol.Approved
MetolazoneThe therapeutic efficacy of Metolazone can be decreased when used in combination with Salsalate.Approved
MetoprololSalsalate may decrease the antihypertensive activities of Metoprolol.Approved, Investigational
MibefradilThe therapeutic efficacy of Mibefradil can be decreased when used in combination with Salsalate.Investigational, Withdrawn
MicronomicinSalsalate may decrease the excretion rate of Micronomicin which could result in a higher serum level.Experimental
MifamurtideThe therapeutic efficacy of Mifamurtide can be decreased when used in combination with Salsalate.Approved, Experimental
MilnacipranMilnacipran may increase the antiplatelet activities of Salsalate.Approved, Investigational
MinoxidilThe therapeutic efficacy of Minoxidil can be decreased when used in combination with Salsalate.Approved, Investigational
MisoprostolThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Salsalate.Approved
MizoribineThe risk or severity of adverse effects can be increased when Mizoribine is combined with Salsalate.Investigational
MoexiprilThe risk or severity of adverse effects can be increased when Salsalate is combined with Moexipril.Approved
MofebutazoneThe risk or severity of adverse effects can be increased when Mofebutazone is combined with Salsalate.Experimental
MometasoneThe risk or severity of adverse effects can be increased when Salsalate is combined with Mometasone.Approved, Vet Approved
MorniflumateThe risk or severity of adverse effects can be increased when Morniflumate is combined with Salsalate.Approved
MoxestrolSalsalate may increase the thrombogenic activities of Moxestrol.Experimental
MoxifloxacinSalsalate may increase the neuroexcitatory activities of Moxifloxacin.Approved, Investigational
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Salsalate.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Salsalate.Approved
NabumetoneThe risk or severity of adverse effects can be increased when Nabumetone is combined with Salsalate.Approved
NadololSalsalate may decrease the antihypertensive activities of Nadolol.Approved
NadroparinSalsalate may increase the anticoagulant activities of Nadroparin.Approved, Investigational
NafamostatThe risk or severity of adverse effects can be increased when Nafamostat is combined with Salsalate.Approved, Investigational
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with Salsalate.Approved
NaftopidilThe therapeutic efficacy of Naftopidil can be decreased when used in combination with Salsalate.Investigational
Nalidixic AcidSalsalate may increase the neuroexcitatory activities of Nalidixic Acid.Approved, Investigational
NaproxenThe risk or severity of adverse effects can be increased when Naproxen is combined with Salsalate.Approved, Vet Approved
NCX 1022The risk or severity of adverse effects can be increased when Salsalate is combined with NCX 1022.Investigational
NeamineSalsalate may decrease the excretion rate of Neamine which could result in a higher serum level.Experimental
NebivololSalsalate may decrease the antihypertensive activities of Nebivolol.Approved, Investigational
NefazodoneNefazodone may increase the antiplatelet activities of Salsalate.Approved, Withdrawn
NemonoxacinSalsalate may increase the neuroexcitatory activities of Nemonoxacin.Investigational
NeomycinThe risk or severity of nephrotoxicity can be increased when Salsalate is combined with Neomycin.Approved, Vet Approved
NepafenacThe risk or severity of adverse effects can be increased when Nepafenac is combined with Salsalate.Approved, Investigational
NetilmicinSalsalate may decrease the excretion rate of Netilmicin which could result in a higher serum level.Approved, Investigational
NicardipineThe therapeutic efficacy of Nicardipine can be decreased when used in combination with Salsalate.Approved, Investigational
NifenazoneThe risk or severity of adverse effects can be increased when Nifenazone is combined with Salsalate.Experimental
Niflumic AcidThe risk or severity of adverse effects can be increased when Salsalate is combined with Niflumic Acid.Approved
NiguldipineThe therapeutic efficacy of Niguldipine can be decreased when used in combination with Salsalate.Experimental
NilvadipineThe therapeutic efficacy of Nilvadipine can be decreased when used in combination with Salsalate.Approved, Investigational
NimesulideThe risk or severity of adverse effects can be increased when Salsalate is combined with Nimesulide.Approved, Investigational, Withdrawn
NimodipineThe therapeutic efficacy of Nimodipine can be decreased when used in combination with Salsalate.Approved, Investigational
NisoldipineThe therapeutic efficacy of Nisoldipine can be decreased when used in combination with Salsalate.Approved
NitrendipineThe therapeutic efficacy of Nitrendipine can be decreased when used in combination with Salsalate.Approved, Investigational
NitroaspirinThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Salsalate.Investigational
NorfloxacinSalsalate may increase the neuroexcitatory activities of Norfloxacin.Approved
OfloxacinSalsalate may increase the neuroexcitatory activities of Ofloxacin.Approved
Oleoyl-estroneThe risk or severity of adverse effects can be increased when Salsalate is combined with Oleoyl-estrone.Investigational
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Salsalate.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Salsalate.Approved
OlsalazineThe risk or severity of adverse effects can be increased when Olsalazine is combined with Salsalate.Approved
Omacetaxine mepesuccinateThe risk or severity of bleeding can be increased when Salsalate is combined with Omacetaxine mepesuccinate.Approved, Investigational
OmapatrilatThe risk or severity of adverse effects can be increased when Salsalate is combined with Omapatrilat.Investigational
OrgoteinThe risk or severity of adverse effects can be increased when Orgotein is combined with Salsalate.Vet Approved
OtamixabanSalsalate may increase the anticoagulant activities of Otamixaban.Investigational
OxaprozinThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Salsalate.Approved
Oxolinic acidSalsalate may increase the neuroexcitatory activities of Oxolinic acid.Experimental
OxprenololSalsalate may decrease the antihypertensive activities of Oxprenolol.Approved
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Salsalate.Approved, Withdrawn
PalmidrolThe risk or severity of adverse effects can be increased when Palmidrol is combined with Salsalate.Experimental, Nutraceutical
PamidronateThe risk or severity of adverse effects can be increased when Salsalate is combined with Pamidronate.Approved
ParamethasoneThe risk or severity of adverse effects can be increased when Salsalate is combined with Paramethasone.Approved
ParecoxibThe risk or severity of adverse effects can be increased when Salsalate is combined with Parecoxib.Approved
ParomomycinThe risk or severity of nephrotoxicity can be increased when Salsalate is combined with Paromomycin.Approved, Investigational
ParoxetineParoxetine may increase the antiplatelet activities of Salsalate.Approved, Investigational
ParthenolideThe risk or severity of adverse effects can be increased when Parthenolide is combined with Salsalate.Approved, Investigational
PazufloxacinSalsalate may increase the neuroexcitatory activities of Pazufloxacin.Investigational
PefloxacinSalsalate may increase the neuroexcitatory activities of Pefloxacin.Approved
PenbutololSalsalate may decrease the antihypertensive activities of Penbutolol.Approved, Investigational
Pentaerythritol TetranitrateSalsalate may increase the anticoagulant activities of Pentaerythritol Tetranitrate.Approved
Pentosan PolysulfateSalsalate may increase the anticoagulant activities of Pentosan Polysulfate.Approved
PerindoprilThe risk or severity of adverse effects can be increased when Salsalate is combined with Perindopril.Approved
PhenindioneSalsalate may increase the anticoagulant activities of Phenindione.Approved, Investigational
PhenprocoumonSalsalate may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational
PhenylbutazoneThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Salsalate.Approved, Vet Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Salsalate.Approved, Investigational
PindololSalsalate may decrease the antihypertensive activities of Pindolol.Approved, Investigational
Pipemidic acidSalsalate may increase the neuroexcitatory activities of Pipemidic acid.Experimental
PiretanideThe therapeutic efficacy of Piretanide can be decreased when used in combination with Salsalate.Approved
PirfenidoneThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Salsalate.Approved, Investigational
Piromidic acidSalsalate may increase the neuroexcitatory activities of Piromidic acid.Experimental
PiroxicamThe risk or severity of adverse effects can be increased when Piroxicam is combined with Salsalate.Approved, Investigational
PirprofenThe risk or severity of adverse effects can be increased when Pirprofen is combined with Salsalate.Experimental
PitolisantThe risk or severity of adverse effects can be increased when Salsalate is combined with Pitolisant.Approved, Investigational
Platelet Activating FactorSalsalate may decrease the antihypertensive activities of Platelet Activating Factor.Experimental
PlazomicinSalsalate may decrease the excretion rate of Plazomicin which could result in a higher serum level.Approved, Investigational
Polyestradiol phosphateSalsalate may increase the thrombogenic activities of Polyestradiol phosphate.Approved
PolythiazideThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Salsalate.Approved
PomalidomideThe risk or severity of adverse effects can be increased when Salsalate is combined with Pomalidomide.Approved
Potassium CitrateSalsalate may increase the anticoagulant activities of Potassium Citrate.Approved, Investigational, Vet Approved
PractololSalsalate may decrease the antihypertensive activities of Practolol.Approved
PralatrexateThe serum concentration of Pralatrexate can be increased when it is combined with Salsalate.Approved, Investigational
PranoprofenThe risk or severity of adverse effects can be increased when Pranoprofen is combined with Salsalate.Experimental, Investigational
PrasteroneThe risk or severity of adverse effects can be increased when Salsalate is combined with Prasterone.Approved, Investigational, Nutraceutical
Prasterone sulfateThe risk or severity of adverse effects can be increased when Salsalate is combined with Prasterone sulfate.Investigational
PrednicarbateThe risk or severity of adverse effects can be increased when Salsalate is combined with Prednicarbate.Approved, Investigational
PrednisoloneThe risk or severity of gastrointestinal irritation can be increased when Prednisolone is combined with Salsalate.Approved, Vet Approved
PrednisoneThe risk or severity of adverse effects can be increased when Salsalate is combined with Prednisone.Approved, Vet Approved
PregnenoloneThe risk or severity of adverse effects can be increased when Salsalate is combined with Pregnenolone.Approved, Experimental, Investigational
ProbenecidThe serum concentration of Salsalate can be increased when it is combined with Probenecid.Approved, Investigational
ProglumetacinThe risk or severity of adverse effects can be increased when Proglumetacin is combined with Salsalate.Experimental
PromestrieneSalsalate may increase the thrombogenic activities of Promestriene.Investigational
PropacetamolThe risk or severity of adverse effects can be increased when Propacetamol is combined with Salsalate.Approved, Investigational
PropafenoneSalsalate may decrease the antihypertensive activities of Propafenone.Approved
PropranololSalsalate may decrease the antihypertensive activities of Propranolol.Approved, Investigational
PropyphenazoneThe risk or severity of adverse effects can be increased when Propyphenazone is combined with Salsalate.Experimental
ProquazoneThe risk or severity of adverse effects can be increased when Proquazone is combined with Salsalate.Experimental
Prostaglandin B2The therapeutic efficacy of Prostaglandin B2 can be decreased when used in combination with Salsalate.Experimental
Prostaglandin G2The therapeutic efficacy of Prostaglandin G2 can be decreased when used in combination with Salsalate.Experimental
ProstaleneThe therapeutic efficacy of Prostalene can be decreased when used in combination with Salsalate.Vet Approved
Protein CSalsalate may increase the anticoagulant activities of Protein C.Approved
Protein S humanSalsalate may increase the anticoagulant activities of Protein S human.Approved
ProtocatechualdehydeSalsalate may increase the anticoagulant activities of Protocatechualdehyde.Approved
PrulifloxacinSalsalate may increase the neuroexcitatory activities of Prulifloxacin.Investigational
PTC299The risk or severity of adverse effects can be increased when PTC299 is combined with Salsalate.Investigational
PuromycinSalsalate may decrease the excretion rate of Puromycin which could result in a higher serum level.Experimental
QuinaprilThe risk or severity of adverse effects can be increased when Salsalate is combined with Quinapril.Approved, Investigational
QuinestrolSalsalate may increase the thrombogenic activities of Quinestrol.Approved
QuinethazoneThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Salsalate.Approved
RamiprilThe risk or severity of adverse effects can be increased when Salsalate is combined with Ramipril.Approved
RescinnamineThe risk or severity of adverse effects can be increased when Salsalate is combined with Rescinnamine.Approved
ResveratrolThe risk or severity of adverse effects can be increased when Salsalate is combined with Resveratrol.Approved, Experimental, Investigational
ReviparinSalsalate may increase the anticoagulant activities of Reviparin.Approved, Investigational
RibostamycinSalsalate may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Approved, Investigational
RimexoloneThe risk or severity of adverse effects can be increased when Salsalate is combined with Rimexolone.Approved
RisedronateThe risk or severity of adverse effects can be increased when Salsalate is combined with Risedronate.Approved, Investigational
RivaroxabanSalsalate may increase the anticoagulant activities of Rivaroxaban.Approved
RofecoxibThe risk or severity of adverse effects can be increased when Rofecoxib is combined with Salsalate.Approved, Investigational, Withdrawn
RosoxacinSalsalate may increase the neuroexcitatory activities of Rosoxacin.Approved, Investigational
RufloxacinSalsalate may increase the neuroexcitatory activities of Rufloxacin.Experimental
SacubitrilThe risk or severity of adverse effects can be increased when Sacubitril is combined with Salsalate.Approved
SalicylamideThe risk or severity of adverse effects can be increased when Salicylamide is combined with Salsalate.Approved
Salicylic acidThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Salsalate.Approved, Investigational, Vet Approved
SaprisartanThe risk or severity of adverse effects can be increased when Saprisartan is combined with Salsalate.Experimental
SaralasinThe risk or severity of adverse effects can be increased when Saralasin is combined with Salsalate.Investigational
SarilumabSarilumab may increase the immunosuppressive activities of Salsalate.Approved, Investigational
SecoisolariciresinolSalsalate may increase the thrombogenic activities of Secoisolariciresinol.Investigational
SeliciclibThe risk or severity of adverse effects can be increased when Salsalate is combined with Seliciclib.Investigational
SemapimodThe risk or severity of adverse effects can be increased when Semapimod is combined with Salsalate.Investigational
SeratrodastThe risk or severity of adverse effects can be increased when Seratrodast is combined with Salsalate.Approved
SerrapeptaseThe risk or severity of adverse effects can be increased when Serrapeptase is combined with Salsalate.Investigational
SertralineSertraline may increase the antiplatelet activities of Salsalate.Approved
SisomicinSalsalate may decrease the excretion rate of Sisomicin which could result in a higher serum level.Investigational
SitafloxacinSalsalate may increase the neuroexcitatory activities of Sitafloxacin.Experimental, Investigational
Sodium CitrateThe risk or severity of bleeding and hemorrhage can be increased when Salsalate is combined with Sodium Citrate.Approved, Investigational
Sodium phosphate, monobasicThe risk or severity of renal failure can be increased when Sodium phosphate, monobasic is combined with Salsalate.Approved
SotalolSalsalate may decrease the antihypertensive activities of Sotalol.Approved
SparfloxacinSalsalate may increase the neuroexcitatory activities of Sparfloxacin.Approved, Investigational
SpiraprilThe risk or severity of adverse effects can be increased when Salsalate is combined with Spirapril.Approved
SpironolactoneThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Salsalate is combined with Spironolactone.Approved
SRT501The risk or severity of adverse effects can be increased when SRT501 is combined with Salsalate.Investigational
StreptomycinSalsalate may decrease the excretion rate of Streptomycin which could result in a higher serum level.Approved, Vet Approved
SulfasalazineThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Salsalate.Approved
SulindacThe risk or severity of adverse effects can be increased when Sulindac is combined with Salsalate.Approved, Investigational
SulodexideSalsalate may increase the anticoagulant activities of Sulodexide.Approved, Investigational
SulprostoneThe therapeutic efficacy of Sulprostone can be decreased when used in combination with Salsalate.Investigational
SuprofenThe risk or severity of adverse effects can be increased when Suprofen is combined with Salsalate.Approved, Withdrawn
SuxibuzoneThe risk or severity of adverse effects can be increased when Suxibuzone is combined with Salsalate.Experimental
Synthetic Conjugated Estrogens, ASalsalate may increase the thrombogenic activities of Synthetic Conjugated Estrogens, A.Approved
Synthetic Conjugated Estrogens, BSalsalate may increase the thrombogenic activities of Synthetic Conjugated Estrogens, B.Approved
TacrolimusSalsalate may increase the nephrotoxic activities of Tacrolimus.Approved, Investigational
TafluprostThe therapeutic efficacy of Tafluprost can be decreased when used in combination with Salsalate.Approved
TalinololSalsalate may decrease the antihypertensive activities of Talinolol.Investigational
TalniflumateThe risk or severity of adverse effects can be increased when Talniflumate is combined with Salsalate.Approved
TarenflurbilThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Salsalate.Investigational
TasosartanThe risk or severity of adverse effects can be increased when Tasosartan is combined with Salsalate.Approved
Technetium Tc-99m etidronateThe risk or severity of adverse effects can be increased when Salsalate is combined with Technetium Tc-99m etidronate.Approved
Technetium Tc-99m medronateThe risk or severity of adverse effects can be increased when Salsalate is combined with Technetium Tc-99m medronate.Approved
TelmisartanThe risk or severity of adverse effects can be increased when Telmisartan is combined with Salsalate.Approved, Investigational
TemafloxacinSalsalate may increase the neuroexcitatory activities of Temafloxacin.Withdrawn
TemocaprilThe risk or severity of adverse effects can be increased when Salsalate is combined with Temocapril.Experimental, Investigational
TenidapThe risk or severity of adverse effects can be increased when Tenidap is combined with Salsalate.Experimental
Tenofovir disoproxilThe risk or severity of adverse effects can be increased when Salsalate is combined with Tenofovir disoproxil.Approved, Investigational
TenoxicamThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Salsalate.Approved
TepoxalinThe risk or severity of adverse effects can be increased when Tepoxalin is combined with Salsalate.Vet Approved
TerbutalineSalsalate may decrease the antihypertensive activities of Terbutaline.Approved
TeriflunomideThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Salsalate.Approved
TertatololSalsalate may decrease the antihypertensive activities of Tertatolol.Experimental
TetrahydropalmatineThe therapeutic efficacy of Tetrahydropalmatine can be decreased when used in combination with Salsalate.Investigational
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Salsalate is combined with Tiaprofenic acid.Approved
TiboloneSalsalate may increase the thrombogenic activities of Tibolone.Approved, Investigational
Tiludronic acidThe risk or severity of adverse effects can be increased when Salsalate is combined with Tiludronic acid.Approved, Investigational, Vet Approved
TimololSalsalate may decrease the antihypertensive activities of Timolol.Approved
TinoridineThe risk or severity of adverse effects can be increased when Tinoridine is combined with Salsalate.Investigational
TioclomarolSalsalate may increase the anticoagulant activities of Tioclomarol.Experimental
TixocortolThe risk or severity of adverse effects can be increased when Salsalate is combined with Tixocortol.Approved, Withdrawn
TobramycinSalsalate may decrease the excretion rate of Tobramycin which could result in a higher serum level.Approved, Investigational
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Salsalate is combined with Tolfenamic Acid.Approved, Investigational
TolmetinThe risk or severity of adverse effects can be increased when Tolmetin is combined with Salsalate.Approved
TorasemideThe therapeutic efficacy of Torasemide can be decreased when used in combination with Salsalate.Approved
TrandolaprilThe risk or severity of adverse effects can be increased when Salsalate is combined with Trandolapril.Approved
TravoprostThe therapeutic efficacy of Travoprost can be decreased when used in combination with Salsalate.Approved
TreprostinilThe risk or severity of adverse effects can be increased when Treprostinil is combined with Salsalate.Approved, Investigational
TriamcinoloneThe risk or severity of adverse effects can be increased when Salsalate is combined with Triamcinolone.Approved, Vet Approved
TriamtereneSalsalate may decrease the antihypertensive activities of Triamterene.Approved
TribenosideThe risk or severity of adverse effects can be increased when Tribenoside is combined with Salsalate.Experimental
TrichlormethiazideThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Salsalate.Approved, Vet Approved
TriptolideThe risk or severity of adverse effects can be increased when Triptolide is combined with Salsalate.Investigational
Trolamine salicylateThe risk or severity of adverse effects can be increased when Salsalate is combined with Trolamine salicylate.Approved
TrovafloxacinSalsalate may increase the neuroexcitatory activities of Trovafloxacin.Approved, Investigational, Withdrawn
TroxerutinSalsalate may increase the anticoagulant activities of Troxerutin.Investigational
UlobetasolThe risk or severity of adverse effects can be increased when Salsalate is combined with Ulobetasol.Approved
UnoprostoneThe therapeutic efficacy of Unoprostone can be decreased when used in combination with Salsalate.Approved, Investigational
ValdecoxibThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Salsalate.Approved, Investigational, Withdrawn
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Salsalate.Approved, Investigational
VancomycinSalsalate may decrease the excretion rate of Vancomycin which could result in a higher serum level.Approved
VenlafaxineVenlafaxine may increase the antiplatelet activities of Salsalate.Approved
WarfarinSalsalate may increase the anticoagulant activities of Warfarin.Approved
XimelagatranSalsalate may increase the anticoagulant activities of Ximelagatran.Approved, Investigational, Withdrawn
ZaltoprofenThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Salsalate.Approved, Investigational
ZeranolSalsalate may increase the thrombogenic activities of Zeranol.Vet Approved
ZileutonThe risk or severity of adverse effects can be increased when Zileuton is combined with Salsalate.Approved, Investigational, Withdrawn
ZimelidineZimelidine may increase the antiplatelet activities of Salsalate.Withdrawn
ZofenoprilThe risk or severity of adverse effects can be increased when Salsalate is combined with Zofenopril.Experimental
Zoledronic acidThe risk or severity of gastrointestinal bleeding can be increased when Salsalate is combined with Zoledronic acid.Approved
ZomepiracThe risk or severity of adverse effects can be increased when Zomepirac is combined with Salsalate.Withdrawn
Food Interactions
Not Available

References

General References
Not Available
External Links
Human Metabolome Database
HMDB0015471
KEGG Drug
D00428
PubChem Compound
5161
PubChem Substance
46506882
ChemSpider
4977
BindingDB
85244
ChEBI
9014
ChEMBL
CHEMBL154111
Therapeutic Targets Database
DAP000734
PharmGKB
PA164745462
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
PDRhealth
PDRhealth Drug Page
Wikipedia
Salsalate
ATC Codes
N02BA06 — Salsalate

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1Active Not RecruitingTreatmentProgressive Supranuclear Palsy (PSP)1
1CompletedBasic ScienceAssessment of Mechanistic Blood Biomarkers in Healthy Humans1
1CompletedBasic ScienceDiabetes Risk1
1CompletedBasic ScienceInsulin Resistance1
1RecruitingTreatmentAlzheimer's Disease (AD)1
1TerminatedBasic SciencePolycystic Ovaries Syndrome1
2Active Not RecruitingTreatmentDiastolic Dysfunction / Endothelial Dysfunction / Vascular Stiffness1
2Active Not RecruitingTreatmentObese / Pre-Diabetic1
2CompletedPreventionBMI >30 kg/m21
2CompletedTreatmentDiabetes, Diabetes Mellitus Type 1 / Peripheral Neuropathy1
2CompletedTreatmentEndothelial Dysfunction / Human Immunodeficiency Virus (HIV) / Inflammatory Reaction / Insulin Resistance1
2Not Yet RecruitingBasic SciencePolycystic Ovaries Syndrome1
2TerminatedTreatmentAnemias1
2, 3Active Not RecruitingPreventionBMI >27 kg/m2 / Coronary Artery Disease1
2, 3CompletedBasic ScienceMetabolic Syndromes1
2, 3CompletedPreventionAtherosclerosis / Cardiovascular Disease (CVD) / Inflammatory Reaction / Insulin Resistance / Noninsulin-dependent Diabetes Mellitus1
2, 3CompletedTreatmentAtherosclerosis1
2, 3CompletedTreatmentType 2 Diabetes Mellitus2
2, 3RecruitingTreatmentDiabetes, Diabetes Mellitus Type 1 / Peripheral Neuropathy1
4Active Not RecruitingTreatmentNon Alcoholic Fatty Liver / Osteo Arthritis1
4CompletedTreatmentDiabetes Mellitus (DM) / Type 2 Diabetes Mellitus1
4CompletedTreatmentSchizoaffective Disorders / Schizophrenic Disorders1
Not AvailableCompletedNot AvailableInsulin Resistant / Pre Diabetes1
Not AvailableCompletedPreventionDiabetes Mellitus (DM) / High Blood Pressure (Hypertension)1
Not AvailableCompletedTreatmentBMI >30 kg/m2 / Pre-Diabetic1
Not AvailableCompletedTreatmentInsulin Resistance / Schizophrenic Disorders1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
  • 3M Health Care
  • Advanced Pharmaceutical Services Inc.
  • Amarin Pharmaceuticals
  • Amerisource Health Services Corp.
  • Amneal Pharmaceuticals
  • Apotheca Inc.
  • AQ Pharmaceuticals Inc.
  • A-S Medication Solutions LLC
  • Boca Pharmacal
  • Caraco Pharmaceutical Labs
  • Comprehensive Consultant Services Inc.
  • DHHS Program Support Center Supply Service Center
  • Direct Dispensing Inc.
  • Dispensing Solutions
  • Diversified Healthcare Services Inc.
  • Golden State Medical Supply Inc.
  • H.J. Harkins Co. Inc.
  • Heartland Repack Services LLC
  • Innoviant Pharmacy Inc.
  • Ivax Pharmaceuticals
  • Kaiser Foundation Hospital
  • Lake Erie Medical and Surgical Supply
  • Liberty Pharmaceuticals
  • Major Pharmaceuticals
  • Murfreesboro Pharmaceutical Nursing Supply
  • Nucare Pharmaceuticals Inc.
  • PD-Rx Pharmaceuticals Inc.
  • Pharmedix
  • Physicians Total Care Inc.
  • Pliva Inc.
  • Prepackage Specialists
  • Prepak Systems Inc.
  • Professional Co.
  • Ranbaxy Laboratories
  • Rebel Distributors Corp.
  • Remedy Repack
  • Resource Optimization and Innovation LLC
  • Sandhills Packaging Inc.
  • Schwarz Pharma Inc.
  • Southwood Pharmaceuticals
  • Sunrise Pharmaceutical Inc.
  • Superior Pharmeceuticals
  • United Research Laboratories Inc.
  • Va Cmop Dallas
Dosage forms
FormRouteStrength
TabletOral500 mg
TabletOral750 mg
TabletOral500 mg/1
TabletOral750 mg/1
Tablet, film coatedOral500 mg/1
Tablet, film coatedOral750 mg/1
Prices
Unit descriptionCostUnit
Salsalate powder16.8USD g
Salsalate 750 mg tablet0.55USD tablet
Salflex-750 tablet0.5USD tablet
Salflex-500 tablet0.37USD tablet
Salsalate 500 mg tablet0.26USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)147 °CPhysProp
Predicted Properties
PropertyValueSource
Water Solubility0.246 mg/mLALOGPS
logP3.44ALOGPS
logP3.64ChemAxon
logS-3ALOGPS
pKa (Strongest Acidic)3.4ChemAxon
pKa (Strongest Basic)-4.3ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area83.83 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity67.1 m3·mol-1ChemAxon
Polarizability24.92 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9161
Blood Brain Barrier+0.8946
Caco-2 permeable+0.5186
P-glycoprotein substrateNon-substrate0.6391
P-glycoprotein inhibitor INon-inhibitor0.8819
P-glycoprotein inhibitor IINon-inhibitor0.9074
Renal organic cation transporterNon-inhibitor0.8788
CYP450 2C9 substrateNon-substrate0.7946
CYP450 2D6 substrateNon-substrate0.9353
CYP450 3A4 substrateNon-substrate0.7281
CYP450 1A2 substrateNon-inhibitor0.7887
CYP450 2C9 inhibitorNon-inhibitor0.5411
CYP450 2D6 inhibitorNon-inhibitor0.9409
CYP450 2C19 inhibitorNon-inhibitor0.8028
CYP450 3A4 inhibitorNon-inhibitor0.9568
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8116
Ames testNon AMES toxic0.9731
CarcinogenicityNon-carcinogens0.8579
BiodegradationReady biodegradable0.5723
Rat acute toxicity2.4607 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9607
hERG inhibition (predictor II)Non-inhibitor0.9403
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Download (7.76 KB)
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as depsides and depsidones. These are polycyclic compounds that is either a polyphenolic compound composed of two or more monocyclic aromatic units linked by an ester bond (depside), or a compound containing the depsidone structure (depsidone).
Kingdom
Organic compounds
Super Class
Phenylpropanoids and polyketides
Class
Depsides and depsidones
Sub Class
Not Available
Direct Parent
Depsides and depsidones
Alternative Parents
o-Hydroxybenzoic acid esters / Salicylic acid and derivatives / Phenol esters / Benzoic acids / Phenoxy compounds / Benzoyl derivatives / 1-hydroxy-4-unsubstituted benzenoids / 1-hydroxy-2-unsubstituted benzenoids / Dicarboxylic acids and derivatives / Vinylogous acids
show 5 more
Substituents
Depside backbone / O-hydroxybenzoic acid ester / Benzoate ester / Salicylic acid or derivatives / Phenol ester / Benzoic acid or derivatives / Benzoic acid / Phenoxy compound / Benzoyl / 1-hydroxy-4-unsubstituted benzenoid
show 14 more
Molecular Framework
Aromatic homomonocyclic compounds
External Descriptors
phenols, salicylates, benzoate ester, benzoic acids (CHEBI:9014)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Prostaglandin-endoperoxide synthase activity
Specific Function
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Constitutively expressed in some tissues in physiological conditions, such as the endothelium, kidney and...
Gene Name
PTGS2
Uniprot ID
P35354
Uniprot Name
Prostaglandin G/H synthase 2
Molecular Weight
68995.625 Da
References
  1. Stichtenoth DO, Zeidler H, Frolich JC: [New non-steroidal anti-rheumatic drugs: selective inhibitors of inducible cyclooxygenase]. Med Klin (Munich). 1998 Jul 15;93(7):407-15. [PubMed:9711054]
  2. Schaefer MG, Plowman BK, Morreale AP, Egan M: Interaction of rofecoxib and celecoxib with warfarin. Am J Health Syst Pharm. 2003 Jul 1;60(13):1319-23. [PubMed:12901032]
  3. Motsko SP, Rascati KL, Busti AJ, Wilson JP, Barner JC, Lawson KA, Worchel J: Temporal relationship between use of NSAIDs, including selective COX-2 inhibitors, and cardiovascular risk. Drug Saf. 2006;29(7):621-32. [PubMed:16808554]
  4. Josephs MD, Cheng G, Ksontini R, Moldawer LL, Hocking MP: Products of cyclooxygenase-2 catalysis regulate postoperative bowel motility. J Surg Res. 1999 Sep;86(1):50-4. [PubMed:10452868]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Prostaglandin-endoperoxide synthase activity
Specific Function
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Involved in the constitutive production of prostanoids in particular in the stomach and platelets. In gas...
Gene Name
PTGS1
Uniprot ID
P23219
Uniprot Name
Prostaglandin G/H synthase 1
Molecular Weight
68685.82 Da
References
  1. Stevenson DD: Aspirin and NSAID sensitivity. Immunol Allergy Clin North Am. 2004 Aug;24(3):491-505, vii. [PubMed:15242723]
  2. Schmidt A, Hescheler J, Offermanns S, Spicher K, Hinsch KD, Klinz FJ, Codina J, Birnbaumer L, Gausepohl H, Frank R, et al.: Involvement of pertussis toxin-sensitive G-proteins in the hormonal inhibition of dihydropyridine-sensitive Ca2+ currents in an insulin-secreting cell line (RINm5F). J Biol Chem. 1991 Sep 25;266(27):18025-33. [PubMed:1680855]
  3. Josephs MD, Cheng G, Ksontini R, Moldawer LL, Hocking MP: Products of cyclooxygenase-2 catalysis regulate postoperative bowel motility. J Surg Res. 1999 Sep;86(1):50-4. [PubMed:10452868]
  4. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]

Drug created on July 08, 2007 11:05 / Updated on August 02, 2018 04:35